TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1
Viruses are able to efficiently penetrate cells, multiply, and eventually kill infected cells, release tumor antigens, and activate the immune system. Therefore, viruses are highly attractive novel agents for cancer therapy. Clinical trials with first generations of oncolytic viruses (OVs) are very...
Saved in:
| Main Authors: | Christina Funk, Nadja Uhlig, Zsolt Ruzsics, Florentin Baur, Matthias Peindl, Sarah Nietzer, Karina Epting, Gabriele Vacun, Gudrun Dandekar, Catherine Botteron, Christian Werno, Thomas Grunwald, Susanne M. Bailer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Molecular Therapy: Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950329924000262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Translation of oncolytic viruses in sarcoma
by: Steven I. Robinson, et al.
Published: (2024-09-01) -
Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysisResearch in context
by: Poyee Lau, et al.
Published: (2025-08-01) -
Clinical trials on oncolytic viruses
by: I. V. Golovinov, et al.
Published: (2025-01-01) -
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis
by: Jia-Li Zhao, et al.
Published: (2024-11-01) -
Measles Virus as a Vector Platform for Glioblastoma Immunotherapy (Review)
by: E. Yu. Nikolaeva, et al.
Published: (2022-02-01)